Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Grant
Filed:
October 2, 2008
Date of Patent:
January 3, 2012
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Application
Filed:
August 9, 2011
Publication date:
November 24, 2011
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Application
Filed:
August 9, 2011
Publication date:
November 24, 2011
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Grant
Filed:
September 12, 2005
Date of Patent:
September 13, 2011
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.
Type:
Application
Filed:
September 11, 2006
Publication date:
August 4, 2011
Applicant:
Rappaport Family institute for Research in the Medical Sciences
Abstract: A method of treating Multiple Sclerosis is disclosed. The method comprises administering to the subject a therapeutically effective amount of SDF-1 alpha. An article of manufacture comprising SDF-1 alpha and an anti-Multiple Sclerosis agent is also disclosed.
Type:
Application
Filed:
February 6, 2008
Publication date:
February 24, 2011
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: The present applications describes, inter alia, a retinal light management system that allows for removal of dangerous wavelengths of light while controlling the intensity of the remaining light that is allowed to pass to a user's eyes. In one embodiment, the system involves a pair of glasses that include filters that can be modified in the presence of light to reduce total light intensity reaching a diabetic's eyes.
Type:
Application
Filed:
July 20, 2008
Publication date:
November 4, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.
Type:
Application
Filed:
May 24, 2010
Publication date:
October 14, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Soluble molecules are provided. Thus, for example, provided is a soluble molecule which comprises a heterologous amino acid sequence conjugated to a CCR5 amino acid sequence being capable of binding a CCR5 ligand, and wherein the molecule is devoid of an N-terminus domain of CCR5. Also provided are pharmaceutical compositions which comprise the above molecules and methods and uses of same.
Type:
Application
Filed:
February 18, 2007
Publication date:
September 9, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: An amino acid sequence derived from the N? terminus region of the 50 Kd subunit of heparanase, preferably, the sequence including amino acid residues Lys158-Asn171 of human heparanase and any functional fragments thereof. Compositions for the inhibition of heparanase glycosidase catalytic activity, having as an active ingredient an isolated and purified peptide as the amino acid sequence. An antibody directed to the sequence and compositions and uses thereof as heparanase inhibitor. The use of the amino acid sequence in a screening method for specific heparanase inhibitors. Compositions including the heparanase inhibitors and methods for the treatment of heparanase related disorders.
Type:
Grant
Filed:
July 28, 2004
Date of Patent:
August 10, 2010
Assignees:
Hadasit Medical Research Services and Development Company, Ltd., Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Israel Vlodavsky, Neta Ilan, Flonia Levy-Adam
Abstract: A method of treating an autoimmune disease such as Multiple Sclerosis is disclosed. The method comprises administering to a subject a therapeutically effective amount of CXCL11. Polypeptides and pharmaceutical compositions for treating same are also disclosed.
Type:
Application
Filed:
June 4, 2008
Publication date:
August 5, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.
Type:
Grant
Filed:
March 14, 2004
Date of Patent:
July 6, 2010
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Methods and kits for diagnosing a lipid-related disorder are disclosed. Methods and pharmaceutical compositions for treating lipid-related disorders are also disclosed.
Type:
Application
Filed:
March 18, 2007
Publication date:
February 4, 2010
Applicant:
Rappaport Family Institute Research in the Medical Sciences
Inventors:
Leonid Gaydukov, Olga Khersonsky, Dan S. Tawfik, Michael Aviram
Abstract: A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype.
Type:
Grant
Filed:
December 31, 2003
Date of Patent:
October 27, 2009
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.
Type:
Grant
Filed:
May 8, 2003
Date of Patent:
March 24, 2009
Assignees:
Rappaport Family Institute for Research in the Medical Sciences, Rockefeller Institute
Inventors:
Hermann Steller, Hyung Don Ryoo, Aaron Ciechanover, Hedva Gonen
Abstract: An isolated polynucleotide is provided, comprising a nucleic acid sequence encoding a soluble polypeptide which comprises an amino acid sequence of an N-terminus domain of CXCR4 and devoid of a CXCR4 extracellular domain selected from the group consisting of ECL1, ECL2 and ECL3, the soluble polypeptide being capable of binding SDF-1. Also provided are methods of using such a nucleic acid sequence such as for the treatment of cancer.
Type:
Application
Filed:
May 25, 2006
Publication date:
February 26, 2009
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of determining a coagulation status of a blood sample is provided. The method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein the ratio is indicative of the coagulation status of the blood sample.
Type:
Application
Filed:
June 23, 2008
Publication date:
February 12, 2009
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and/or to prevent or treat metastasis.
Type:
Application
Filed:
September 20, 2006
Publication date:
October 9, 2008
Applicant:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Nicola J. Nasser, Aaron Avivi, Israel Vlodavsky, Eviatar Nevo
Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or attenuation of anthracycline-induced cardiotoxicity.
Type:
Application
Filed:
October 18, 2007
Publication date:
April 17, 2008
Applicants:
Technion Research and Development Foundation Ltd., Rappaport Family Institute for Research in the Medical Sciences